Suchergebnisse - "Lederer, David J"

PubPharm (12)

1

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease : a double-blind, randomised, placebo-controlled, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2020

von Maher, T. | Corte, T. | Fischer, A. | +8

CommentIn: Lancet Respir Med. 2020 Feb;8(2):126-127. - PMID 31578170

2

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis : Optimising Trial Design

enthalten in: Advances in therapy | 2019

von Santermans, E. | Ford, P. | Kreuter, M. | +11

3

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis : Impact of Timing of Treatment Initiation

enthalten in: Annals of the American Thoracic Society | 2019

von Maher, T. | Lancaster, L. | Jouneau, S. | +9

4

Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis

enthalten in: Chest | 2019

von Nathan, S. | Costabel, U. | Glaspole, I. | +8

5

Idiopathic Pulmonary Fibrosis

enthalten in: The New England journal of medicine | 2018

von Lederer, D. | Martinez, F.

CommentIn: N Engl J Med. 2018 Aug 23;379(8):795-6. - PMID 30136547

6

Effect of pirfenidone on mortality : pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis

enthalten in: The Lancet. Respiratory medicine | 2017

von Nathan, S. | Albera, C. | Bradford, W. | +12

CommentIn: Lancet Respir Med. 2017 Jan;5(1):3-5. - PMID 27876248

7

Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis : a randomised, double-blind, controlled, phase 2 trial

enthalten in: The Lancet. Respiratory medicine | 2017

von Raghu, G. | Brown, K. | Collard, H. | +18

CommentIn: Lancet Respir Med. 2017 Jan;5(1):2-3. - PMID 27939077

8

Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function

enthalten in: The European respiratory journal | 2016

von Albera, C. | Costabel, U. | Fagan, E. | +7

9

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity : analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis

enthalten in: Thorax | 2016

von Nathan, S. | Albera, C. | Bradford, W. | +16

CommentIn: Thorax. 2016 May;71(5):399-400. - PMID 27068097

10

Pirfenidone for idiopathic pulmonary fibrosis : analysis of pooled data from three multinational phase 3 trials

enthalten in: The European respiratory journal | 2016

von Noble, P. | Albera, C. | Bradford, W. | +14

CommentIn: Eur Respir J. 2016 Jan;47(1):27-30. - PMID 26721960